Malaria diagnostic system

LAP242AUndetermined Publication Date: 2025-09-08UNIVERSITI MALAYA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP242
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2010-08-13
Filing Date
2011-06-28
Publication Date
2025-09-08

AI Technical Summary

Technical Problem

Current malaria diagnosis methods, particularly PCR techniques, face challenges in sensitivity, specificity, cost-effectiveness, and complexity, especially in detecting multiple Plasmodium species simultaneously, with existing multiplex PCR methods only capable of detecting up to two species and requiring complex procedures.

Method used

A single-step multiplex PCR method using specifically designed nucleotide fragment pairs and primer pairs for detecting P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi, optimized for simultaneous detection with high sensitivity and specificity, utilizing interspecies-conserved and species-specific sequences of the 18S small subunit ribosomal RNA.

Benefits of technology

Enables rapid, cost-effective, and accurate detection of all four main human malaria parasites in a single step, improving upon existing methods by enhancing sensitivity and specificity while simplifying the diagnostic process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

This invention discloses obtaining of a multiplex PCR-based detection system targeting 5 types of Plasmodium sepsis (P. falciparum, P. Malariae, P. ovale). Generally, all novel primers used in the present invention were specially designed using bioinformatics approach. This system involved only 1 step PCR with specific optimized conditions. This PCR-based detection system is sensitive enough to detect particular plasmodium species at low parasitemia level.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] A DIAGNOSTIC SYSTEM FOR MALARIA FIELD OF THE INVENTION

[0002] The present invention relates to a development of a more sensitive, specific, cost- 5 effective, as well as single step multiplex polymerase chain reaction (PCR) method for the diagnosis of five main human malaria parasites, P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi.

[0003] BACKGROUND OF THE INVENTION

[0004] 10 Malaria remains one of the major killers of humans worldwide, threatening the lives of more than one-third of the world's population. Malaria is widespread in many tropical and subtropical areas, including parts of America, many parts of Asia and Africa. Forty percent of the world population lives in the endemic areas. Each year, there are at least 300-500 million clinical cases of malaria reported worldwide with —1-5 1.5-2.7 million deaths, occurring mostly in children under 5 years old (Greenwood BM, Bojang K, Whitty CJM, Targett GAT (2005) Malaria. Lancet 365: 1487-1498; http: / / www.cdc.gov / malaria / ; http: / / rbm.who.int / wmr2005 / ).

[0005] According to World Malaria Report 2005, the reported malaria cases in Malaysia are 20 6,338 (including 861 imported cases) with 21 confirmed malaria deaths in the year 2003. Overall, Sarawak state consists the highest reported cases with 2,615 cases, followed by Sabah with 1 ,770 cases and Pahang with 850 cases (http: / / www.rbm.who.int / wmr2005 / profiles / malaysia.pdf).

[0006] 25 Human malaria is commonly resulted by the infection with one or mixed of the four species of Plasmodium parasites, i.e., P. vivax, P. falciparum, P. malariae, and P. ovale. However, in some circumstances, the simian Plasmodium, i.e., P. knowlesi was also reported in human (Singh B, Sung L , Matusop A, Radhakrishnan A, Shamsul v SGS, Cox-Singh J, ThomasA, and Conway DJ (2004) A large focus of naturally

[0007] 30 acquired Plasmodium knowlesi infections in human beings. Lancet 363: 1017-1024;Jongwutiwes S, Putaporntip C, Iwasaki T, Sata T, and anbara H (2004) Naturally acquired Plasmodium knowlesi Malaria in human, Thailand. Emerg. Infect. Dis. 10:221 1-2213). In 2004, Singh et al. reported that all of the previously reported P. malariae infections in Sarawak (within March 2000 to November 2002) were actually P. knowlesi based on nested polymerase chain reaction (PCR) assay. P. knowlesi is known to be morphologically identical to P. malariae based on microscopic identification (Singh B, Sung L , Matusop A, Radhakrishnan A, Shamsul SGS, Cox- Singh J, ThomasA, and Conway DJ (2004) A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363: 1017-1024).

[0008] In general, P . vivax is the most common cause of infection, responsible for about 80 % of all malaria cases, followed by P. falciparum that is responsible for about 15 % of infections and 90 % of deaths (Mendis K, Sina B, Marchesini P, and Carter R (2001 ) The neglected burden of Plasmodium vivax malaria. Am. J. Prop. Med. Hyg. 64:97-106). Whereas, disease caused by P. ovale and P. malariae are relatively rare. In Sarawak, P. vivax is the predominant species followed by P. falciparum, P. malariae (which many have been re-identified as P. knowlesi via molecular identification) and mixed species infection. There has been no reported case of P. ovale (Singh B, Sung LK, Matusop A, Radhakrishnan A, Shamsul SGS, Cox-Singh J, ThomasA, and Conway DJ (2004) A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363: 1017-1024).

[0009] The Plasmodium parasites live part of its life in human and part in mosquitoes (genus Anopheles). Infected female Anopheles plays a role as vector in human-human transmission. The life cycle of Plasmodium species is extraordinarily complex and specific for the particular parasite species. In general, it can be distinguished into three main stage-cycles, i.e., exo-erythrocytic and erythrocytic cycles in human host, and sporogonic cycle in mosquito. Generally, the erythrocytic stage parasites are responsible for the clinical manifestations of the disease. Thus, it serves as an important diagnostic stage in malaria.To date, there are several methods used worldwide for diagnosing Plasmodium species infection in blood. In general, microscopy examination of Giemsa-stained thin and / or thick blood films remains the gold standard for routine laboratory diagnosis of malaria (Warhurst DC and Williams JE (1996) Laboratory diagnosis of malaria. J. Clin. Pathol. 49:533-538). This inexpensive and rapid assay enables identification of plasmodial species and quantification of parasites, both of which are important in assessing the disease severity and prescription of adequate therapy. However, the sensitivity drops with the decrease of parasitemia as well as in cases of mixed infection, which potentially leading to false negative or unreliable species determination (Rougemont M, Saanen MV, Sahli R, Hinrikson HP, Bille J, and Jaton K (2004) Detection of four Plasmodium species in blood from human by 18S rRNA gene subunit-based and species-specific real-time PCR assays. J Clin. Microbiol. 42:5636-5643). Recently, various immunochromatographic dipstick kits are commercially available (Chiodini, PL, Bowers , Jorgensen P, Barnwell JW, Grady K, Luchavez J, Moody AH, Cemzal A and Bell D (2007). The heat stability of Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests. Trans. R. Soc. Prop. Med. Hyg. 101 :331 -337). However, most of the kits cannot accurately diagnose the species of plasmodial infection in human (Moody A (2002) Rapid diagnostic tests for malaria parasites. Clin. Microbiol. Rev. 15:66-78).

[0010] Nowadays, PCR methods, such as nested PCR, multiplex PCR and real-time PCR offers an alternative to microscopic examination. The PCR assays are based on the amplification of gene sequence using primers of interspecies-conserved and species- specific sequence of the 18S small subunit ribosomal RNA (ssrRNA). Therefore, it can successfully detect the parasites in cases of mixed infections as well as those with low parasitemia. Although PCR methods have shown in many cases to have superior sensitivity and specificity for the diagnosis of malaria, there are several limitations. In general, PCR methods are relatively time-consuming (especially nested PCR), expensive (real-time PCR) and also required complex procedures. Amongst the PCR methods, multiplex PCR seems to be the most ideally assay in malaria detection, however, there are lack of the disclosure in this area due to the difficulties in primersdesign as well as various optimization procedure. To date, the detection level of published multiplex PCR is only up to two species, i.e., P. falciparum and P. vivax ( ho WG, Chung JY, Sim EJ, Kim MY, Kim DW, Jongwutiwes S, and Tanabe K (2003) A multiplex polymerase chain reaction for a differential diagnosis of Plasmodium falciparum and Plasmodium vivax. Parasitol. Int. 52:229-236; Padley D, Moody AH, Chiodini PL, and Saldanha J (2003) Use of a rapid, single-round, multiplex PCR to detect malarial parasites and identify the species present. Ann. Trop. Med. Parasitol. 97: 131-137; Patsoula E, Spanakos G, Sofianatou D, Parara M, and Vakalis NC (2003) A single-step, PCR-based method for the detection and differentiation of Plasmodium vivax and P. falciparum. Ann. Trop. Med. Parasitol. 97: 15-21). Therefore, it is important to develop a more convenient as well as single step multiplex PCR assay in identification of all human Plasmodium species in malaria disease.

[0011] SUMMARY OF THE INVENTION

[0012] An object of the present invention is to provide a single step multiplex PCR method for the diagnosis of five main human malaria parasites, P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi. Another object of the present invention is to provide a nucleotide fragment pair comprising base sequence (SEQ ID NO: l) and (SEQ ID NO:6) represented by the following sequence (SEQ ID NO: l) and (SEQ ID NO:6), a base sequence pair complementary thereto or a mutation sequence thereof; and a primer pair for detecting the P. falciparum malaria parasite comprising the following nucleotide fragments:

[0013] 5 'ATTTAAAACCTTCCC AGAGTAAC3 ' (SEQ ID NO: l)

[0014] 5 ' GAATTTC ACCTCTGAC ATCTG3 ' (SEQ ID NO:6)

[0015] Further object of the present invention is to provide a nucleotide fragment pair comprising a base sequence (SEQ ID NO:2) and (SEQ ID NO:6) represented by the following sequence (SEQ ID NO:2) and (SEQ ID NO:6), a base sequence paircomplementary thereto or a mutation sequence thereof; and a primer pair for detecting the P. malariae malaria parasite comprising the following nucleotide fragments:

[0016] 5 'TGTATATTTATAACAAAGTTGTAC3 ' (SEQ ID NO:2) 5 ' GA ATTTC ACCTCTG AC ATCTG3 ' (SEQ ID NO:6)

[0017] Still further object of the present invention is to provide a nucleotide fragment pair comprising a base sequence (SEQ ID NO:3) and (SEQ ID NO:6) represented by the following sequence (SEQ ID NO:3) and (SEQ ID NO:6), a base sequence pair complementary thereto or a mutation sequence thereof; and a primer pair for detecting the P. ovale malaria parasite comprising the following nucleotide fragments:

[0018] 5 ' A AG ATGCTTAGAC A AT AC A ACG3 ' (SEQ ID NO:3)

[0019] 5 'GAATTTC ACCTCTG AC ATCTG3' (SEQ ID NO:6)

[0020] Yet still further object of the present invention is to provide a nucleotide fragment pair comprising a base sequence (SEQ ID NO:4) and (SEQ ID NO:6) represented by the following sequence (SEQ ID NO:4) and (SEQ ID NO:6), a base sequence pair complementary thereto or a mutation sequence thereof; and a primer pair for detecting the P. knowlesi malaria parasite comprising the following nucleotide fragments:

[0021] 5 ' CTTTATGTGCGC ATCCTCTAC3 ' (SEQ ID NO:4)

[0022] 5'GAATTTCACCTCTGACATCTG3' (SEQ ID NO:6)

[0023] Yet still further object of the present invention is to provide a nucleotide fragment pair comprising a base sequence (SEQ ID NO:5) and (SEQ ID NO:6) represented by the following sequence (SEQ ID NO:5) and (SEQ ID NO:6), a base sequence pair complementary thereto or a mutation sequence thereof; and a primer pair for detecting the P. vivax malaria parasite comprising the following nucleotide fragments:5 'GACTTTCTTTGCTTCGGCTTG3 ' (SEQ ID NO:5) 5 ' GAATTTC ACCTCTGAC ATCTG3 ' (SEQ ID NO:6)

[0024] BRIEF DESCRIPTION OF THE DRAWING FIGURES

[0025] Figure 1 : A copy of photographic representation showing PCR amplification products generated using the combination of primers SEQ ID NO: 1 to 5 together with SEQ ID NO: 6.

[0026] DETAIL DESCRIPTION OF THE PRESENT INVENTION

[0027] A single step multiplex PCR method for the diagnosis of five main human malaria parasites, P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi in accordance with the present invention will herein below be described in further detail.

[0028] Search and analysis of various published sequences of different Plasmodium species in database are carried out. Multiplex oligonucleotide primers are designed based on the interspecies conserved and species-specific sequences of the ssrRNA. PCR of each primer are initially optimized individually in monoplex condition and later on combined and further optimized to obtain a multiplex condition.

[0029] In order to determine the detection limit of a multiplex PCR, recombinant plasmids of each species containing a fragment from the 18S ssrRNA gene are constructed. PCR products (P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi) are purified and ligated into the TOPO TA cloning pCR®IIvector (Invitrogen) and transformed into Top 10 competent E. coli. Isolation of recombinant plasmid DNA is performed with QIAprep Miniprep (Qiagen) and the presence of the correct insen is confirmed by sequencing. The 6 specific primers represented by the sequences (SEQ ID NO: l to 6) have been developed in the present invention can be classified in the following manner according to their characteristics.(A) A primer pair for selectively detecting the P. falciparum malaria parasite comprising 2 nucleotide fragments:

[0030] 5'GAAAATTCCTTTCGGGGA3' (SEQ ID NO: 1)

[0031] 5'GAATTTCACCTCTGACATCTG3' (SEQ ID NO:6)

[0032] (B) A primer pair for selectively detecting the P. malariae malaria parasite comprising 2 nucleotide fragments:

[0033] 5'TGTATATTTATAACAAAGTTGTAC3 ' (SEQ ID NO:2)

[0034] ' GAATTTC ACCTCTG AC ATCTG3 ' (SEQ ID NO:6)

[0035] (C) A primer pair for selectively detecting the P. ovale malaria parasite comprising 2 nucleotide fragments:

[0036] 5 ' AAGATGCTT AG AC AATAC AACG3 ' (SEQ ID NO:3)

[0037] 5 ' GAATTTC ACCTCTG AC ATCTG3 ' (SEQ ID NO:6)

[0038] (D) A primer pair for selectively detecting the P. knowlesi malaria parasite comprising 2 nucleotide fragments:

[0039] 5 ' CTTTATGTGCGC ATCCTCTAC3 ' (SEQ ID NO:4)

[0040] 5 ' GAATTTC ACCTCTG AC ATCTG3 ' (SEQ ID NO:6)

[0041] (E) A primer pair for selectively detecting the P. vivax malaria parasite comprising 2 nucleotide fragments:

[0042] 5 ' GACTTTCTTTGCTTCGGCTTG3 ' (SEQ ID NO:5)

[0043] 5 ' GAATTTC ACCTCTG AC ATCTG3 ' (SEQ ID NO:6)

[0044] When the nucleotide fragments according to the present invention which have the above-mentioned base sequences, respectively, are used as a primer or primers either singly or in various combinations with one another, five Plasmodium spp (P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi) can be detected easily, rapidly, cost-effectively and with a high sensitivity at the same time or distinguished accurately from one another.To further illustrate the present invention in greater detail and not by the way of limitation, the following examples will be given.

[0045] Example

[0046] Blind test on approximately 100 clinical samples were carried out with the developed multiplex PCR assay for sensitivity and specificity studies.

[0047] Whole blood samples from patients with suspected malaria (by Giemsa's stained thin and / or thick smear and microscopic examination) were obtained. DNA is extracted from thawed, three repeated PBS washed and followed by 0.05 % saponin treated anti-coagulated-blood using QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions.

[0048] The extracted DNA was subjected to optimum PCR condition using 15 μΐ working PCR mixture which comprise 6 specific primers (SEQ ID NO: 1 tcr ) and certain chemicals. The optimum PCR conditions to obtain the expected results is 95 °C for 3 min (1 cycle); 95 °C for 30 sec, 56 °C for 30 sec, 65 °C for 40 sec (35 cycles); 65 °C for 10 min (1 cycle). The formulation and concentration of the working PCR mixture listed as below:

[0049] Then, PCR products were resolved in 3% (w / v) agarose gel. The results are shown in Figure 1 and Table 1. The nucleotide fragment with the SEQ ID NO: 1 to 6 used in the polymerase chain reaction produces amplified DNA fragments based on the Plasmodium species (451 bp for P. falciparum; 339 bp for P. malariae; 304 bp for P. ovale; 284 bp for P. knowlesi and 215 bp for P. vivax)

[0050] Table 1

Claims

1. A nucleotide fragment consisting of a base sequence represented by the following sequence:5 ' ATTT A AA ACCTTCCC AG AGT A AC3 ' (SEQ ID NO: 1) or the base sequence complementary thereto.

2. A nucleotide fragment consisting of a base sequence represented by the following sequence:5 'TGTATATTTATAACAAAGTTGTAC3 ' (SEQ ID NO:2) or the base sequence complementary thereto.

3. A nucleotide fragment consisting of a base sequence represented by the following sequence:5 ' A AGATGCTT AG AC A ATAC AACG3 ' ~ (SEQ ID NO:3) or the base sequence complementary thereto.

4. A nucleotide fragment consisting of a base sequence represented by the following sequence:5'CTTTATGTGCGCATCCTCTAC3' (SEQ ID NO:4) or the base sequence complementary thereto.

5. A nucleotide fragment consisting of a base sequence represented by the following sequence:5 ' G ACTTTCTTTGCTTCGGCTTG3 ' (SEQ ID NC ) or the base sequence complementary thereto.

6. A nucleotide fragment consisting of a base sequence represented by the following sequence:5 ' GAATTTC ACCTCTGACATCTG3 ' (SEQ ID NO:6) or the base sequence complementary thereto.

7. A one step multiplex PCR method for the diagnosis of five Plasmodium spp malaria parasites, P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi comprising nucleotide fragments represented by the following sequences:5'ATTTAAAACCTTCCCAGAGTAAC3' (SEQ ID NOrl)5 'TGTATATTTATAACAAAGTTGTAC3 ' (SEQ ID NO:2)5 'AAGATGCTTAGACAATACAACG3 ' (SEQ ID NO:3)5 ' CTTTATGTGCGC ATCCTCTAC3 ' (SEQ ID NO:4)5 ' GACTTTCTTTGCTTCGGCTTG3 ' (SEQ ID NO:5) 5 ' G AATTTC ACCTCTGAC ATCTG3 ' (SEQ ID NO:6) or the base sequences complementary thereto.

8. The method according to claim 7, wherein the optimized PCR condition to obtain the expected results is 95 °C for 3 min (1 cycle); 95 °C for 30 sec, 56 °C for 30 sec, 65 °C for 40 sec (35-cycles); 65 °C for 10 min (1 cycle).

9. Primers of single PCR for detecting one of five different Plasmodium spp malaria parasites, P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi comprising nucleotide fragments represented by a combination of one of the following sequences (SEQ ID NO: 1 to 5) with (SEQ ID NO:6)5 'ATTTAAAACCTTCCC AGAGTAAC3 ' (SEQ ID NO: 1)5 ' TGTATATTT ATAAC AAAGTTGT AC3 ' (SEQ ID NO:2)5 ' AAGATGCTT AG AC AATAC AACG3 ' (SEQ ID NO:3)5' CTTTATGTGCGC ATCCTCTAC3' (SEQ ID NO:4) 5 ' GACTTTCTTTGCTTCGGCTTG3 ' (SEQ ID NO:5)5'GAATTTCACCTCTGACATCTG3' (SEQ ID NO:6) or the base sequences complementary thereto.

10. The primers according to claim 9, wherein the optimized PCR condition to obtain the expected results is 95 °C for 3 min (1 cycle); 95 °C for 30 sec, 56 °C for 30 sec, 65 °C for 40 sec (35 cycles); 65 °C for 10 min (1 cycle).